Darwin AG: issuer report for the first half of 2025

Munich 02/20/2025 (pta010/02.10.2025/10:00 UTC+2)

Darwin AG (ISIN DE000A3C35W0) today published its issuer report as of June 30, 2025.

In the first half of 2025, the Group more than doubled revenue compared with the prior-year period to approximately €27.6 million and generated consolidated net income after taxes of around €2.0 million.

" The revenue increases in the first half have so far met our high expectations for the 2025 financial year," reports CEO Dr. Daniel Wallerstorfer. "We will confirm this revenue trend in the second half of the year and are pleased with the very strong performance of our Group" the company founder added.

The report is available for download at https://darwin-biotech.com/financial-reports/.

Background

The "Darwin Group" (i.e. Darwin AG including its subsidiaries), headquartered in Munich (Germany), is a European biotechnology company, particularly in the field of human genetics. The genetic analyses carried out in our own laboratory are used in diagnostics, therapy and prevention of diseases as well as in the production of individually designed nutritional supplements and cosmetics. Darwin also acts as a partner for doctors, therapists, pharmacists, nutritionists or fitness trainers and, by analyzing the respective genetic predisposition of the patient or customer, helps to ensure the best possible treatment or care for their needs. Darwin also invests in innovative companies in the biotech, healthcare and life sciences sectors.

(end)

Emitter:	Darwin AG Brienner Straße 7 80333 München Germany
Contact Person:	Daniel Wallerstorfer
Phone:	+49 89 20 500 450
E-Mail:	investor.relations@darwin-biotech.com
Website:	www.darwin-biotech.com
ISIN(s):	DE000A3C35W0 (Share)
Stock Exchange(s):	Free Market in Frankfurt, Munich (m:access)